Search Results
An introduction to the MAPK signaling pathway and pan-RAF inhibitors
Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers
Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers
JNK Signaling Pathway - BOC Sciences
A Phase Ia/Ib trial of BGB-3245, a novel RAF dimer inhibitor, in solid tumors
Webinar: First-in Human-Studies of FGFR Inhibitor KIN-3248 and RAF Inhibitor KIN-2787
Lalaoui N (2015): Targeting IAPs and p38 MAPK to treat cancer
MAPK Pathway Aberrations in Head and Neck Cancer
Beyond EGFR and VEGFR inhibitors: Targeting the RAS/RAF/MEK and alternative pathway in CRC
RAS Oncoproteins Therapeutic Vulnerabilities
RAS Oncoproteins Therapeutic Vulnerabilities
Benefits and drawbacks of combinations of BRAF inhibitors and immunotherapy
